#BEGIN_DRUGCARD DB03397

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H27N3O17P2

# Chemical_IUPAC_Name:
[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2S,3S,4S,5R,6S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Uridine-Diphosphate-N-Acetylglucosamine

# HET_ID:
UD1

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11-,12-,13-,14+,15+,16-/m0/s1

# InChI_Key:
InChIKey=LFTYTUAZOPRMMI-LSIJYXAZSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3397

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
607.3537

# Molecular_Weight_Mono:
607.081569477

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JVD

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
1.14e+01 g/l

# Primary_Accession_No:
DB03397

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936661

# PubChem_Substance_ID:
46506870

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03168

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1O)N1C=CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:13 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X01631

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
glmU

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
6395859	Walker JE, Gay NJ, Saraste M, Eberle AN: DNA sequence around the Escherichia coli unc operon. Completion of the sequence of a 17 kilobase segment containing asnA, oriC, unc, glmS and phoS. Biochem J. 1984 Dec 15;224(3):799-815.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
8083170	Mengin-Lecreulx D, van Heijenoort J: Copurification of glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J Bacteriol. 1994 Sep;176(18):5788-95.
8407787	Mengin-Lecreulx D, van Heijenoort J: Identification of the glmU gene encoding N-acetylglucosamine-1-phosphate uridyltransferase in Escherichia coli. J Bacteriol. 1993 Oct;175(19):6150-7.
8555230	Gehring AM, Lees WJ, Mindiola DJ, Walsh CT, Brown ED: Acetyltransfer precedes uridylyltransfer in the formation of UDP-N-acetylglucosamine in separable active sites of the bifunctional GlmU protein of Escherichia coli. Biochemistry. 1996 Jan 16;35(2):579-85.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3697

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
49191

# Drug_Target_1_Name:
Bifunctional protein glmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase

# Drug_Target_1_Number_of_Residues:
456

# Drug_Target_1_PDB_ID:
1HV9

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00132	Hexapep
PF01128	IspD

# Drug_Target_1_Protein_Sequence:
>Bifunctional protein glmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase
MLNNAMSVVILAAGKGTRMYSDLPKVLHTLAGKAMVQHVIDAANELGAAHVHLVYGHGGD
LLKQALKDDNLNWVLQAEQLGTGHAMQQAAPFFADDEDILMLYGDVPLISVETLQRLRDA
KPQGGIGLLTVKLDDPTGYGRITRENGKVTGIVEHKDATDEQRQIQEINTGILIANGADM
KRWLAKLTNNNAQGEYYITDIIALAYQEGREIVAVHPQRLSEVEGVNNRLQLSRLERVYQ
SEQAEKLLLAGVMLRDPARFDLRGTLTHGRDVEIDTNVIIEGNVTLGHRVKIGTGCVIKN
SVIGDDCEISPYTVVEDANLAAACTIGPFARLRPGAELLEGAHVGNFVEMKKARLGKGSK
AGHLTYLGDAEIGDNVNIGAGTITCNYDGANKFKTIIGDDVFVGSDTQLVAPVTVGKGAT
IAAGTTVTRNVGENALAISRVPQTQKEGWRRPVKKK

# Drug_Target_1_Reaction:
UTP + N-acetyl-alpha-D-glucosamine 1-phosphate = diphosphate + UDP-N-acetyl-D-glucosamine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-GlcNAc. Responsible for the acetylation of Glc-N-1-P to give GlcNAc-1-P and for the uridyl transfer from UTP to GlcNAc-1-P which produces UDP-GlcNAc

# Drug_Target_1_SwissProt_ID:
P0ACC7

# Drug_Target_1_SwissProt_Name:
GLMU_ECOLI

# Drug_Target_1_Synonyms:
EC 2.3.1.157]
EC 2.7.7.23
Glucosamine-1-phosphate N-acetyltransferase
N-acetylglucosamine-1-phosphate uridyltransferase

# Drug_Target_1_Theoretical_pI:
6.52

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm. Note=In spermatozoa, localized to the principal piece of the tail, the neck region of the

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
UAP1

# Drug_Target_2_GenBank_ID_Gene:
S73498

# Drug_Target_2_GenBank_ID_Protein:
7717462

# Drug_Target_2_GeneCard_ID:
UAP1

# Drug_Target_2_Gene_Name:
UAP1

# Drug_Target_2_Gene_Sequence:
>1518 bp
ATGAACATTAATGACCTCAAACTCACGTTGTCCAAAGCTGGGCAAGAGCACCTACTACGT
TTCTGGAATGAGCTTGAAGAAGCCCAACAGGTAGAACTTTATGCAGAGCTCCAGGCCATG
AACTTTGAGGAGCTGAACTTCTTTTTCCAAAAGGCCATTGAAGGTTTTAACCAGTCTTCT
CACCAAAAGAATGTGGATGCACGAATGGAACCTGTGCCTCGAGAGGTATTAGGCAGTGCT
ACAAGGGATCAAGATCAGCTCCAGGCCTGGGAAAGTGAAGGACTTTTCCAGATTTCTCAG
AATAAAGTAGCAGTTCTTCTTCTAGCTGGTGGGCAGGGGACAAGACTCGGCGTTGCATAT
CCTAAGGGGATGTATGATGTTGGTTTGCCATCCCGTAAGACACTTTTTCAGATTCAAGCA
GAGCGTATCCTGAAGCTACAGCAGGTTGCTGAAAAATATTATGGCAACAAATGCATTATT
CCATGGTATATAATGACCAGTGGCAGAACAATGGAATCTACAAAGGAGTTCTTCACCAAG
CACAAGTACTTTGGTTTAAAAAAAGAGAATGTAATCTTTTTTCAGCAAGGAATGCTCCCC
GCCATGAGTTTTGATGGGAAAATTATTTTGGAAGAGAAGAACAAAGTTTCTATGGCTCCA
GATGGGAATGGTGGTCTTTATCGGGCACTTGCAGCCCAGAATATTGTGGAGGATATGGAG
CAAAGAGGCATTTGGAGCATTCATGTCTATTGTGTTGACAACATATTAGTAAAAGTGGCA
GACCCACGGTTCATTGGATTTTGCATTCAGAAAGGAGCAGACTGTGGAGCAAAGGTGGTA
GAGAAAACGAACCCTACAGAACCAGTTGGAGTGGTTTGCCGAGTGGATGGAGTTTACCAG
GTGGTAGAATATAGTGAGATTTCCCTGGCAACAGCTCAAAAACGAAGCTCAGACGGACGA
CTGCTGTTCAATGCGGGGAACATTGCCAACCATTTCTTCACTGTACCATTTCTGAGAGAT
GTTGTCAATGTTTATGAACCTCAGTTGCAGCACCATGTGGCTCAAAAGAAGATTCCTTAT
GTGGATACCCAAGGACAGTTAATTAAGCCAGACAAACCCAATGGAATAAAGATGGAAAAA
TTTGTCTTTGACATCTTCCAGTTTGCAAAGAAGTTTGTGGTATATGAAGTATTGCGAGAA
GATGAGTTTTCCCCACTAAAGAATGCTGATAGTCAGAATGGGAAAGACAACCCTACTACT
GCAAGGCATGCTTTGATGTCCCTTCATCATTGCTGGGTCCTCAATGCAGGGGGCCATTTC
ATAGATGAAAATAGCTCTCGCCTTCCAGCAATTCCCCGCTTGAAGGATGCCAATGATGTA
CCAATCCAATGTGAAATCTCTCCTCTTATCTCCTATGCTGGAGAAGGATTAGAAAGTTAT
GTGGCAGATAAAGAATTCCATGCACCTCTAATCATCGATGAGAATGGAGTTCATGAGCTG
GTGAAAAATGGTATTTGA

# Drug_Target_2_General_Function:
Involved in nucleotidyltransferase activity

# Drug_Target_2_General_References:
8025165	Diekman AB, Goldberg E: Characterization of a human antigen with sera from infertile patients. Biol Reprod. 1994 May;50(5):1087-93.
9603950	Mio T, Yabe T, Arisawa M, Yamada-Okabe H: The eukaryotic UDP-N-acetylglucosamine pyrophosphorylases. Gene cloning, protein expression, and catalytic mechanism. J Biol Chem. 1998 Jun 5;273(23):14392-7.
9765219	Wang-Gillam A, Pastuszak I, Elbein AD: A 17-amino acid insert changes UDP-N-acetylhexosamine pyrophosphorylase specificity from UDP-GalNAc to UDP-GlcNAc. J Biol Chem. 1998 Oct 16;273(42):27055-7.

# Drug_Target_2_HGNC_ID:
HGNC:12457

# Drug_Target_2_HPRD_ID:
04178

# Drug_Target_2_ID:
2612

# Drug_Target_2_Locus:
1q23.3

# Drug_Target_2_Molecular_Weight:
58770

# Drug_Target_2_Name:
UDP-N-acetylhexosamine pyrophosphorylase

# Drug_Target_2_Number_of_Residues:
522

# Drug_Target_2_PDB_ID:
1JVG

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01704	UDPGP

# Drug_Target_2_Protein_Sequence:
>UDP-N-acetylhexosamine pyrophosphorylase
MNINDLKLTLSKAGQEHLLRFWNELEEAQQVELYAELQAMNFEELNFFFQKAIEGFNQSS
HQKNVDARMEPVPREVLGSATRDQDQLQAWESEGLFQISQNKVAVLLLAGGQGTRLGVAY
PKGMYDVGLPSRKTLFQIQAERILKLQQVAEKYYGNKCIIPWYIMTSGRTMESTKEFFTK
HKYFGLKKENVIFFQQGMLPAMSFDGKIILEEKNKVSMAPDGNGGLYRALAAQNIVEDME
QRGIWSIHVYCVDNILVKVADPRFIGFCIQKGADCGAKVVEKTNPTEPVGVVCRVDGVYQ
VVEYSEISLATAQKRSSDGRLLFNAGNIANHFFTVPFLRDVVNVYEPQLQHHVAQKKIPY
VDTQGQLIKPDKPNGIKMEKFVFDIFQFAKKFVVYEVLREDEFSPLKNADSQNGKDNPTT
ARHALMSLHHCWVLNAGGHFIDENGSRLPAIPRSATNGKSETITADVNHNLKDANDVPIQ
CEISPLISYAGEGLESYVADKEFHAPLIIDENGVHELVKNGI

# Drug_Target_2_Reaction:
UTP + N-acetyl-alpha-D-glucosamine 1-phosphate = diphosphate + UDP-N-acetyl-D-glucosamine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Converts UDP and GlcNAc-1-P into UDP-GlcNAc, and UDP and GalNAc-1-P into UDP-GalNAc. Isoform AGX1 has 2 to 3 times higher activity towards GalNAc-1-P, while isoform AGX2 has 8 times more activity towards GlcNAc-1-P

# Drug_Target_2_SwissProt_ID:
Q16222

# Drug_Target_2_SwissProt_Name:
UAP1_HUMAN

# Drug_Target_2_Synonyms:
AGX
AGX-1
Antigen X
EC 2.7.7.-
EC 2.7.7.23
Sperm- associated antigen 2
UDP-N-acetylglucosamine pyrophosphorylase

# Drug_Target_2_Theoretical_pI:
6.29

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE005674

# Drug_Target_3_GenBank_ID_Protein:
24053661

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
murA

# Drug_Target_3_Gene_Sequence:
>1260 bp
TTACTCGCCTTTCACACGCTCAATATTTGCACCTAAAGCGCGCAGTTTGTCTTCAATGCG
TTCGTAGCCACGATCGATGTGATAAATACGATCAACCACCGTCGTCCCTTCCGCAATACA
GCCAGCCAGCACCAGGCTTGCTGATGCACGCAGATCGGTTGCCATAACCTGTGCACCAGA
AAGTTTTTCAACACCATGACAAATAACGGTATTGCTTTCGATTTCGGCGTGCGCGCCCAT
ACGGCTCAGCTCTGGCACATGCATAAAGCGGTTTTCAAAGACCGTTTCGGTGATGAACCC
GGTCCCTTCAGCCACCAGGTTCAACAGCGTGAACTGGGCCTGCATATCGGTCGGGAATGC
CGGATGCGGCGCGGTACGTACGTTAACAGCCTTCGGACGTTTGCCATGCATATCCAGGCT
AATCCAGTCTTCGCCGACTTCGATGTCCGCTCCAGCATCACGCAGTTTCGCCAGCACGGC
GTCCAGAGTATCTGGCTGCGCGTTACGGCAGATAATTTTGCCACGAGAGATCGCCGCCGC
CACCAGGAAAGTACCGGTTTCGATACGATCCGGCAGCACGCGATAGACACCGCCGCCTAA
ACGTTCCACACCTTCGATGACGATACGATCGGTGCCCTGACCGCTAATTTTCGCACCCAG
CGTAATCAGGAAGTTCGCGGTATCGACGATTTCCGGTTCACGCGCTGCGTTTTCAATAAT
CGTGGTGCCTTCCGCCAGGGTTGCAGCACACATGATGGTCACCGTTGCGCCAACGCTGAC
TTTATCCATCACGATATGTGCGCCTTTCAGACGACCATCGACGGAAGCTTTAACGTAACC
TTCTTCCAGTTTGATGGTCGCGCCTAATTGTTCGAGGCCAGAAATGTGTAGATCAACCGG
ACGCGCACCGATCGTACAACCGCCAGGTAGTGAAACTTGCCCCTGACCAAAGCGCGCTAC
CAGCGGCCCCAGCGCCCAGATAGAAGCACGCATGGTTTTAACCAGATCGTAAGGTGCGCA
GAATACATTAACGTCGCGGGCATCAATATGCACAGAACCATTACGTTCTACTTTCGCACC
CAGCTGGCTTAGCAGTTTCATTGATGTATCGACGTCTTTCAGTTTCGGGACGTTCTGGAT
CTCTACCGGTTCTTCCGCCAGTAGTGCGGCAAAAAGAATAGGCAGAGCAGCATTTTTAGC
GCCGGAAATTGTGACTTCGCCCTGGAGCTTCGTTGGCCCCTGAACACGAAATTTATCCAT

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2306

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
44818

# Drug_Target_3_Name:
UDP-N-acetylglucosamine 1-carboxyvinyltransferase

# Drug_Target_3_Number_of_Residues:
419

# Drug_Target_3_PDB_ID:
1UAE

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00275	EPSP_synthase

# Drug_Target_3_Protein_Sequence:
>UDP-N-acetylglucosamine 1-carboxyvinyltransferase
MDKFRVQGPTKLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDVDTSMKLLSQL
GAKVERNGSVHIDARDVNVFCAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCTIGAR
PVDLHISGLEQLGATIKLEEGYVKASVDGRLKGAHIVMDKVSVGATVTIMCAATLAEGTT
IIENAAREPEIVDTANFLITLGAKISGQGTDRIVIEGVERLGGGVYRVLPDRIETGTFLV
AAAISRGKIICRNAQPDTLDAVLAKLRDAGADIEVGEDWISLDMHGKRPKAVNVRTAPHP
AFPTDMQAQFTLLNLVAEGTGFITETVFENRFMHVPELSRMGAHAEIESNTVICHGVEKL
SGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE

# Drug_Target_3_Reaction:
phosphoenolpyruvate + UDP-N-acetyl-D-glucosamine = phosphate + UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Cell wall formation. Adds enolpyruvyl to UDP-N- acetylglucosamine

# Drug_Target_3_SwissProt_ID:
P0A751

# Drug_Target_3_SwissProt_Name:
MURA_SHIFL

# Drug_Target_3_Synonyms:
EC 2.5.1.7
EPT
Enoylpyruvate transferase
UDP-N-acetylglucosamine enolpyruvyl transferase

# Drug_Target_3_Theoretical_pI:
6.07

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
GALE

# Drug_Target_4_GenBank_ID_Gene:
L41668

# Drug_Target_4_GenBank_ID_Protein:
1119217

# Drug_Target_4_GeneCard_ID:
GALE

# Drug_Target_4_Gene_Name:
GALE

# Drug_Target_4_Gene_Sequence:
>1047 bp
ATGGCAGAGAAGGTGCTGGTAACAGGTGGGGCTGGCTACATTGGCAGCCACACGGTGCTG
GAGCTGCTGGAGGCTGGCTACTTGCCTGTGGTCATCGATAACTTCCATAATGCCTTCCGT
GGAGGGGGCTCCCTGCCTGAGAGCCTGCGGCGGGTCCAGGAGCTGACAGGCCGCTCTGTG
GAGTTTGAGGAGATGGACATTTTGGACCAGGGAGCCCTACAGCGTCTCTTCAAAAAGTAC
AGCTTTATGGCGGTCATCCACTTTGCGGGGCTCAAGGCCGTGGGCGAGTCGGTGCAGAAG
CCTCTGGATTATTACAGAGTTAACCTGACCGGGACCATCCAGCTTCTGGAGATCATGAAG
GCCCACGGGGTGAAGAACCTGGTGTTCAGCAGCTCAGCCACTGTGTACGGGAACCCCCAG
TACCTGCCCCTTGATGAGGCCCACCCCACGGGTGGTTGTACCAACCCTTACGGCAAGTCC
AAGTTCTTCATCGAGGAAATGATCCGGGACCTGTGCCAGGCAGACAAGACTTGGAACGTA
GTGCTGCTGCGCTATTTCAACCCCACAGGTGCCCATGCCTCTGGCTGCATTGGTGAGGAT
CCCCAGGGCATACCCAACAACCTCATGCCTTATGTCTCCCAGGTGGCGATCGGGCGACGG
GAGGCCCTGAATGTCTTTGGCAATGACTATGACACAGAGGATGGCACAGGTGTCCGGGAT
TACATCCATGTCGTGGATCTGGCCAAGGGCCACATTGCAGCCTTAAGGAAGCTGAAAGAA
CAGTGTGGCTGCCGGATCTACAACCTGGGCACGGGCACAGGCTATTCAGTGCTGCAGATG
GTCCAGGCTATGGAGAAGGCCTCTGGGAAGAAGATCCCGTACAAGGTGGTGGCACGGCGG
GAAGGTGATGTGGCAGCCTGTTACGCCAACCCCAGCCTGGCCCAAGAGGAGCTGGGGTGG
ACAGCAGCCTTAGGGCTGGACAGGATGTGTGAGGATCTCTGGCGCTGGCAGAAGCAGAAT
CCTTCAGGCTTTGGCACGCAAGCCTGA

# Drug_Target_4_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_4_General_References:
10801319	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry. 2000 May 16;39(19):5691-701.
11279193	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J Biol Chem. 2001 Jun 8;276(23):20617-23. Epub 2001 Mar 7.
8593531	Daude N, Gallaher TK, Zeschnigk M, Starzinski-Powitz A, Petry KG, Haworth IS, Reichardt JK: Molecular cloning, characterization, and mapping of a full-length cDNA encoding human UDP-galactose 4'-epimerase. Biochem Mol Med. 1995 Oct;56(1):1-7.
9326324	Quimby BB, Alano A, Almashanu S, DeSandro AM, Cowan TM, Fridovich-Keil JL: Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. Am J Hum Genet. 1997 Sep;61(3):590-8.
9538513	Maceratesi P, Daude N, Dallapiccola B, Novelli G, Allen R, Okano Y, Reichardt J: Human UDP-galactose 4' epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. Mol Genet Metab. 1998 Jan;63(1):26-30.
9973283	Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL: Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am J Hum Genet. 1999 Feb;64(2):462-70.

# Drug_Target_4_HGNC_ID:
HGNC:4116

# Drug_Target_4_HPRD_ID:
06092

# Drug_Target_4_ID:
2762

# Drug_Target_4_Locus:
1p36-p35

# Drug_Target_4_Molecular_Weight:
38282

# Drug_Target_4_Name:
UDP-glucose 4-epimerase

# Drug_Target_4_Number_of_Residues:
348

# Drug_Target_4_PDB_ID:
1EK6

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_4_Protein_Sequence:
>UDP-glucose 4-epimerase
MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGRSV
EFEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMK
AHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNA
VLLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRD
YIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVARR
EGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA

# Drug_Target_4_Reaction:
UDP-glucose = UDP-galactose

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Catalyzes two distinct but analogous reactions:the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N- acetylgalactosamine

# Drug_Target_4_SwissProt_ID:
Q14376

# Drug_Target_4_SwissProt_Name:
GALE_HUMAN

# Drug_Target_4_Synonyms:
EC 5.1.3.2
Galactowaldenase
UDP-galactose 4-epimerase

# Drug_Target_4_Theoretical_pI:
6.71

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AE005672

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
glmU

# Drug_Target_5_Gene_Sequence:
>1380 bp
ATGTCAAATTTTGCCATTATTTTAGCAGCGGGTAAAGGGACTCGCATGAAATCTGATTTG
CCAAAAGTTTTGCACAAGGTTGCGGGTATTTCTATGTTGGAACATGTTTTCCGTAGTGTG
GGAGCTATCCAACCTGAAAAGACAGTAACAGTTGTAGGACACAAGGCAGAATTGGTTGAG
GAGGTCTTGGCTGGACAGACAGAATTTGTGACTCAATCTGAACAGTTGGGAACTGGTCAT
GCAGTTATGATGACAGAGCCTATCTTAGAAGGTTTGTCAGGACACACCTTGGTCATTGCA
GGAGATACTCCTTTAATCACTGGTGAAAGCTTGAAAAACTTGATTGATTTCCATATCAAT
CATAAAAATGTGGCCACTATCTTGACTGCTGAAACGGATAATCCTTTTGGTTATGGACGA
ATTGTTCGTAATGACAATGCTGAGGTTCTTCGTATTGTTGAGCAGAAGGATGCTACAGAT
TTTGAAAAGCAAATCAAGGAAATCAACACTGGAACATACGTCTTTGACAACGAGCGTTTG
TTTGAGGCTTTGAAAAATATCAATACCAATAACGCTCAAGGCGAATACTATATTACAGAC
GTCATTGGTATTTTCCGTGAAACTGGTGAAAAAGTTGGCGCTTATACTTTGAAAGATTTT
GATGAAAGTCTTGGGGTAAATGACCGTGTGGCGCTTGCGACAGCTGAGTCAGTTATGCGT
CGTCGCATCAATCATAAACACATGGTCAACGGTGTTAGCTTTGTCAATCCAGAAGCAACT
TATATCGATATTGATGTTGAGATTGCTTCGGAAGTTCAAATCGAAGCCAATGTTACCTTG
AAAGGGCAAACGAAAATTGGTGCTGAGACTGTTTTGACAAACGGTACTTATGTAGTGGAC
AGCACTATCGGAGCAGGAGCGGTCATTACCAATTCTATGATTGAGGAAAGTAGTGTTGCA
GACGGTGTGATAGTCGGTCCTTATGCTCACATTCGTCCAAATTCAAGTCTGGGTGCCCAA
GTTCATATTGGTAACTTTGTTGAGGTGAAAGGATCTTCAATCGGTGAGAATACCAAGGCT
GGTCATTTGACTTATATCGGAAACTGTGAAGTGGGAAGCAACGTTAATTTCGGTGCTGGA
ACTATTACAGTCAACTATGACGGCAAAAACAAATACAAGACAGTCATTGGAAACAATGTC
TTTGTTGGTTCAAATTCAACCATTATTGCACCAGTAGAACTTGGTGACAATTCCCTCGTT
GGTGCTGGTTCAACTATTACTAAAGACGTGCCAGCAGATGCTATTGCTATTGGTCGCGGT
CGTCAGATCAATAAAGACGAATATGCAACACGTCTTCCTCATCATCCTAAGAACCAGTAG

# Drug_Target_5_General_Function:
Involved in UDP-N-acetylglucosamine diphosphorylase activity

# Drug_Target_5_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5252

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
49345

# Drug_Target_5_Name:
Bifunctional protein glmU

# Drug_Target_5_Number_of_Residues:
459

# Drug_Target_5_PDB_ID:
1G97

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00132	Hexapep
PF01128	IspD

# Drug_Target_5_Protein_Sequence:
>Bifunctional protein glmU
MSNFAIILAAGKGTRMKSDLPKVLHKVAGISMLEHVFRSVGAIQPEKTVTVVGHKAELVE
EVLAGQTEFVTQSEQLGTGHAVMMTEPILEGLSGHTLVIAGDTPLITGESLKNLIDFHIN
HKNVATILTAETDNPFGYGRIVRNDNAEVLRIVEQKDATDFEKQIKEINTGTYVFDNERL
FEALKNINTNNAQGEYYITDVIGIFRETGEKVGAYTLKDFDESLGVNDRVALATAESVMR
RRINHKHMVNGVSFVNPEATYIDIDVEIASEVQIEANVTLKGQTKIGAETVLTNGTYVVD
STIGAGAVITNSMIEESSVADGVIVGPYAHIRPNSSLGAQVHIGNFVEVKGSSIGENTKA
GHLTYIGNCEVGSNVNFGAGTITVNYDGKNKYKTVIGNNVFVGSNSTIIAPVELGDNSLV
GAGSTITKDVPADAIAIGRGRQINKDEYATRLPHHPKNQ

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-GlcNAc. Responsible for the acetylation of Glc-N-1-P to give GlcNAc-1-P and for the uridyl transfer from UTP to GlcNAc-1-P which produces UDP-GlcNAc (Probable)

# Drug_Target_5_SwissProt_ID:
Q97R46

# Drug_Target_5_SwissProt_Name:
GLMU_STRPN

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
5.43

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X06226

# Drug_Target_6_GenBank_ID_Protein:
41523

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
galE

# Drug_Target_6_Gene_Sequence:
>1017 bp
ATGAGAGTTCTGGTTACCGGTGGTAGCGGTTACATTGGAAGTCATACCTGTGTGCAATTA
CTGCAAAACGGTCATGATGTCATCATTCTTGATAACCTCTGTAACAGTAAGCGCAGCGTA
CTGCCTGTTATCGAGCGTTTAGGCGGCAAACATCCAACGTTTGTTGAAGGCGATATTCGT
AACGAAGCGTTGATGACCGAGATCCTGCACGATCACGCTATCGACACCGTGATCCACTTC
GCCGGGCTGAAAGCCGTGGGCGAATCGGTACAAAAACCGCTGGAATATTACGACAACAAT
GTCAACGGCACTCTGCGCCTGATTAGCGCCATGCGCGCCGCTAACGTCAAAAACTTTATT
TTTAGCTCCTCCGCCACCGTTTATGGCGATCAGCCCAAAATTCCATACGTTGAAAGCTTC
CCGACCGGCACACCGCAAAGCCCTTACGGCAAAAGCAAGCTGATGGTGGAACAGATCCTC
ACCGATCTGCAAAAAGCCCAGCCGGACTGGAGCATTGCCCTGCTGCGCTACTTCAACCCG
GTTGGCGCGCATCCGTCGGGCGATATGGGCGAAGATCCGCAAGGCATTCCGAATAACCTG
ATGCCATACATCGCCCAGGTTGCTGTAGGCCGTCGCGACTCGCTGGCGATTTTTGGTAAC
GATTATCCGACCGAAGATGGTACTGGCGTACGCGATTACATCCACGTAATGGATCTGGCG
GACGGTCACGTCGTGGCGATGGAAAAACTGGCGAACAAGCCAGGCGTACACATCTACAAC
CTCGGCGCTGGCGTAGGCAACAGCGTGCTGGACGTGGTTAATGCCTTCAGCAAAGCCTGC
GGCAAACCGGTTAATTATCATTTTGCACCGCGTCGCGAGGGCGACCTTCCGGCCTACTGG
GCGGACGCCAGCAAAGCCGACCGTGAACTGAACTGGCGCGTAACGCGCACACTCGATGAA
ATGGCGCAGGACACCTGGCACTGGCAGTCACGCCATCCACAGGGATATCCCGATTAA

# Drug_Target_6_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_6_General_References:
1579570	Bauer AJ, Rayment I, Frey PA, Holden HM: The molecular structure of UDP-galactose 4-epimerase from Escherichia coli determined at 2.5 A resolution. Proteins. 1992 Apr;12(4):372-81.
2134186	Bernardi F, Bernardi A: Completed sequence of pKG1800, a vector for determination of transcription terminators. DNA Seq. 1990;1(2):147-50.
3022232	Lemaire HG, Muller-Hill B: Nucleotide sequences of the gal E gene and the gal T gene of E. coli. Nucleic Acids Res. 1986 Oct 10;14(19):7705-11.
6301942	Busby S, Dreyfus M: Segment-specific mutagenesis of the regulatory region in the Escherichia coli galactose operon: isolation of mutations reducing the initiation of transcription and translation. Gene. 1983 Jan-Feb;21(1-2):121-31.
8564363	Walkenhorst HM, Hemschemeier SK, Eichenlaub R: Molecular analysis of the molybdate uptake operon, modABCD, of Escherichia coli and modR, a regulatory gene. Microbiol Res. 1995 Nov;150(4):347-61.
8611559	Thoden JB, Frey PA, Holden HM: Crystal structures of the oxidized and reduced forms of UDP-galactose 4-epimerase isolated from Escherichia coli. Biochemistry. 1996 Feb 27;35(8):2557-66.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
8931134	Thoden JB, Frey PA, Holden HM: High-resolution X-ray structure of UDP-galactose 4-epimerase complexed with UDP-phenol. Protein Sci. 1996 Nov;5(11):2149-61.
9174344	Thoden JB, Hegeman AD, Wesenberg G, Chapeau MC, Frey PA, Holden HM: Structural analysis of UDP-sugar binding to UDP-galactose 4-epimerase from Escherichia coli. Biochemistry. 1997 May 27;36(21):6294-304.
9271499	Thoden JB, Gulick AM, Holden HM: Molecular structures of the S124A, S124T, and S124V site-directed mutants of UDP-galactose 4-epimerase from Escherichia coli. Biochemistry. 1997 Sep 2;36(35):10685-95.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9708982	Thoden JB, Holden HM: Dramatic differences in the binding of UDP-galactose and UDP-glucose to UDP-galactose 4-epimerase from Escherichia coli. Biochemistry. 1998 Aug 18;37(33):11469-77.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3461

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
37266

# Drug_Target_6_Name:
UDP-glucose 4-epimerase

# Drug_Target_6_Number_of_Residues:
338

# Drug_Target_6_PDB_ID:
2UDP

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_6_Protein_Sequence:
>UDP-glucose 4-epimerase
MRVLVTGGSGYIGSHTCVQLLQNGHDVIILDNLCNSKRSVLPVIERLGGKHPTFVEGDIR
NEALMTEILHDHAIDTVIHFAGLKAVGESVQKPLEYYDNNVNGTLRLISAMRAANVKNFI
FSSSATVYGDQPKIPYVESFPTGTPQSPYGKSKLMVEQILTDLQKAQPDWSIALLRYFNP
VGAHPSGDMGEDPQGIPNNLMPYIAQVAVGRRDSLAIFGNDYPTEDGTGVRDYIHVMDLA
DGHVVAMEKLANKPGVHIYNLGAGVGNSVLDVVNAFSKACGKPVNYHFAPRREGDLPAYW
ADASKADRELNWRVTRTLDEMAQDTWHWQSRHPQGYPD

# Drug_Target_6_Reaction:
UDP-glucose = UDP-galactose

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
UDP-glucose = UDP-galactose

# Drug_Target_6_SwissProt_ID:
P09147

# Drug_Target_6_SwissProt_Name:
GALE_ECOLI

# Drug_Target_6_Synonyms:
EC 5.1.3.2
Galactowaldenase
UDP-galactose 4-epimerase

# Drug_Target_6_Theoretical_pI:
6.32

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Not Available

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
EXTL2

# Drug_Target_7_Gene_Sequence:
Not Available

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
7139

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
Not Available

# Drug_Target_7_Name:
Exostosin-like 2

# Drug_Target_7_Number_of_Residues:
0

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
Not Available

# Drug_Target_7_Protein_Sequence:
Not Available

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
Not Available

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Q9UBQ6

# Drug_Target_7_SwissProt_Name:
EXTL2_HUMAN

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
Not Available

# Drug_Target_7_Transmembrane_Regions:
Not Available

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
Not Available

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
MGAT1

# Drug_Target_8_Gene_Sequence:
Not Available

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
7029

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
Not Available

# Drug_Target_8_Name:
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

# Drug_Target_8_Number_of_Residues:
0

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
Not Available

# Drug_Target_8_Protein_Sequence:
Not Available

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
Not Available

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
P26572

# Drug_Target_8_SwissProt_Name:
MGAT1_HUMAN

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
Not Available

# Drug_Target_8_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB03397
